Studies using FABP1 immunohistochemistry have so far described FABP1 positivity in 47–100% of hepatocellular carcinomas [12, 13], 47.4–83.3% of various subtypes of lung cancer [14], 30–81.5% of colorectal carcinomas [15, 16], 38.6% of gastric adenocarcinomas [17], 27–36.4% of various kidney cancer subtypes [18], and in 12.1% of pancreatic carcinomas [19]. The gene discussed is FABP1; the disease is kidney cancer.